Commentary on chapter by Klintmalm: Tacrolimus by Starzl, TE & Fung, JJ
b 
Blackwell 
Science 
Transplantation 
Edited by 
LEO C. GINNS, MD 
Associate Professor of Medicine 
Harvard Medical School; 
Medical Director 
Lung Transplant Program 
Massachusetts General Hospital 
Boston, Massachusetts 
A. BENEDICT COSIMI, MD 
Claude E. Welch Professor of Surgery 
Harvard Medical School; 
Chief, Transplantation Unit 
Massachusetts General Hospital 
Boston, Massachusetts 
PETER J. MORRIS, MB, PhD, FRS 
Nuffield Department of Surgery 
University of Oxford; 
Oxford Radcliffe Hospital 
Oxford, England 
( hap t e r 
Tacrolimus 
GORAN B. KUNTMALM 
HISTORY 
Tacrolimus (FKS06, Prograf; Fujisawa, Deerfield, IL, USA) is 
a macrolide compound isolated from Streptomyces tsukubaen-
sis, a soil fungus that can be found in Northern Japan (1). 
Its immunosuppressive properties were fmt recognized in 
1984 during a screening program directed at identifYing 
new immunosuppressive agents. Subsequent in vitro and 
animal experiments in Japan and at the University of Pitts-
burgh helped to characterize the mechanism of action of 
tacrolimus and demonstrated its potent immunosuppressive 
properties in transplantation (1-6). 
IMMUNOLOGY 
Most clinically useful immunosuppressive drugs either 
inhibit the proliferation ofT lymphocytes or destroy them. 
Cyclosporine inhibits cytokine synthesis by binding to 
cytoplasmic proteins (cyclophylins) in T lymphocytes (see 
Chapter 6). Tacrolimus functions in a similar fashion, binding 
to FK-binding proteins (FKBP) in the cytoplasm; however, 
tacrolimus has a greater binding affinity to FKBP than does 
cyclosporine to cyclophilin. Rapamycin, which is struc-
turally similar to tacrolimus, does not inhibit cytokine 
synthesis but rather inhibits the response ofT cells to inter-
leukin 2 (IL-2) and other cytokines (see Chapters 6 and 
11) . 
The complex formed by the binding of tacrolimus to 
FKBP-12 associates with calcium-dependent calcineurinl 
calmodulin complexes to impede calcium-dependent signal 
transduction subsequent to stimulation of calcium influx in 
lymphocytes. Transcription factors that promote cytokine 
gene activation are direct or indirect substrates for cal-
cineurin, and their activity is reduced by association with 
the tacrolimus complex. Tacrolimus inhibits the mixed lym-
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phocyte reaction assay, the formation of IL-2 by T lym-
phocytes, and formation of other soluble mediators includ-
ing IL-3, IL-4, IL-S, tumor necrosis factor alpha (TNF-a), 
and granulocyte-macrophage-colony stimulating factor (7). 
Tacrolimus also inhibits the expression of IL-2 and IL-7 
receptors. As an immunosuppressive agent, tacrolimus is 
approximately 100 times more potent than cyclosporine (8). 
PHARMACOKINETICS AND MONITORING 
Tacrolimus achieves adequate absorption from the upper 
small intestine following oral administration, but the extent 
of absorption is widely variable (range = 5% to 67%) among 
patients. Administration with food generally does not affect 
the oral absorption of tacrolimus, although fatty meals may 
reduce bioavailability (9). Because absorption is bile inde-
pendent, intravenous administration is not required in most 
patients (as is often required with cyclosporine [Sandim-
mUl1e], particularly during the early postoperative period), 
and dosage changes are not required when clamping a T-
tube following liver transplantation (10). 
During liver graft failure or hepatic dysfunction, espe-
cially with cholestasis, tacrolimus bioavailability increases and 
clearance decreases owing to its extensive hepatic metabo-
lism. The result is markedly elevated tacrolimus levels with 
related toxicity necessitating a rapid reduction in dosage 
(10,11). In contrast, initial dosing reductions usually are not 
required in patients with renal impairment (10). 
Tacrolimus concentrations can be measured either in 
whole blood or plasma using an enzyme-linked immunosor-
bent assay (ELISA) (12) or in whole blood with a micro-
particle enzyme immunoassay (13). Measurement of plasma 
tacrohmus concentrations may be less desirable both because 
of the complexity of the methodology and because plasma 
must be separated at 37° C due to temperature-dependent 
127 
128 PART II Immunosuppression 
distribution of tacrolimus into erythrocytes, similar to that 
of cyclosporine (14). Importantly, plasma levels of tacrolimus 
measured by ELISA were found to correlate poorly with 
rejection and toxicity (15), whereas whole blood tacrolimus 
levels were well correlated with rejection and toxicity 
(16). Other studies indicated a higher correlation of 
plasma tacrolimus levels with clinical events (17). As with 
cyclosporine, plasma level monitoring can be used if samples 
are handled carefully. However, because of the technical dif-
ficulties inherent in plasma level monitoring, whole blood 
levels are usually considered the standard of care. 
During oral therapy with tacrolimus, concentrations 
should be monitored to maintain 12-hour trough levels in 
the range of 5 to 15 ng/mL for whole blood or 0.5 to 1.5 
ng/mL for plasma to optimize efficacy and minimize 
toxicity. Clinical experience has shown that high trough 
tacrolimus levels correlate with a lower incidence of rejec-
tion, and high peak levels correlate with increased toxicity 
(18,19). A definite correlation between tacrolimus levels and 
nephrotoxicity has not been recognized, but a reduction in 
serum creatinine levels was reported in liver transplant recip-
ients when tacrolimus levels were reduced (17). 
PRECLINICAL EXPERIENCE 
WITH TACROLIMUS 
Numerous animal studies have been conducted demonstrat-
ing the in vitro and in vivo effects of tacrolimus (Table 9.1) 
(20). Although many studies have evaluated the use of 
tacrolimus in preventing graft rejection, the published liter-
ature has also described the effects of tacrolimus on the 
inhibition of cell-mediated responses, proliferative responses, 
cytotoxic responses, and humoral responses, as well as its 
effect on various autoimmune disorders. 
An in vitro study evaluated the etfect of tacrolimus com-
pared to cyclosporine and prednisolone on the mixed lym-
Table 9.1. Experimental Autoimmune Diseases Suppressed by Tacrolimus 
DIsease 
Arthritis (Type II collagen-induced) 
Type 1 diabetes 
Uveoretinitis 
Thyroiditis 
Lupus (SLE) 
Glomerulonephritis 
(Nephrotoxic antiserum nephritis) 
Heymann nephritis 
Allergic encephalomyelitis 
Autoimmune myocarditis 
Experimental allergic contact dermatitis 
Murine (coxsackie Bl) myocarditis 
• Suppresses induction of disease. 
Species 
Rat (Lewis) 
Rat (Outbred) 
Mouse (OBAll) 
NOD mouse 
Cyclophosphamide-treated NOD mouse 
BB rat 
BB rat 
Rat (Lewis) 
Rhesus and cynomolgus monkeys 
Rat (PVG) 
MRL-Ipr/lpr mouse 
NZBINZW F' mouse 
Rat (Wistar) 
Rat (Wistar) 
Rat (Wistar) 
Rat (Lewis) 
Rat (Lewis) 
Rat (Lewis) 
Farm pig 
Mice (OHIHe) 
Partially effective during efferent phase of response. 
C On day of immunization. 
Administered daily from 27-120 days of age. 
e Effective only in induction phase. 
Administered from 3 weeks after immunization. 
9 Administered for 3 weeks follOWing induction of disease. 
h Administered from 8 weeks of age. 
i From time of immunization. 
) Administered 5 days per week after immunization. 
k Administered from day 0-13 or 56-69. 
Tacrolimus Dose (mglkg/day unless specified) Reference 
0.32,·b Inamura et ai, 1988 (21) 
2.5' Arita et ai, 1990 (22) 
2.0 Takagishi et ai, 1989 (23) 
2.0mg/kg/48 h' Miyagawa et ai, 1990 (24) 
0.2, 1.0, 2.0 Carroll et ai, 1991 (25) 
1.0' Murase et ai, 1990 (26) 
Op~g IMd Nicoletti et ai, 1991 (27) 
to'" Kawashima et ai, 1990 (28) 
O.Sf Fujino et a!, 1990 (29) 
2.09 Tamura et ai, 1992 (30) 
2mgh Yamamoto et ai, 1988 (31) 
2.5 mg/kg/48 hi Takabayashi et a!, 1989 (32) 
lKPm~ Hara et ai, 1990 (33) 
0.64 Okuba et ai, 1990 (34) 
0.64 Okuba et ai, 1990 (34) 
1.0 Matsukawa et ai, 1992 (35) 
1.0 Inamura et ai, 1988 (36) 
1.0,0.32,1.0 Hanawa et ai, 1992 (37) 
0.04,0.4% topical Meingassner and Stutz, 1992 (38) 
2.5 Hiraoka et ai, 1992 (39) 
Adapted from Thomson AW, Murase N. Nalesnik MA. Starzl TE. The influence of tacrolimus on experimental autoimmune disease. In: Lieberman R. Mukherjee A. eds. 
Principles of drug development in transplantation and autoimmunity. Austin, TX: RG Landes. 1996. 
phocvte reaction (MLR) E:~FK Tacrolinllls demonstrated 
dose-dependent suppression of the proliferative response of 
human lymphocvtes to allo:mtigen stimulation at con-
centrations higher than 0.1 nmoliL. The IC;o val'les of 
tacrolimus, cyclosporine, and prednisolone were 0.22, 14.0, 
and HO.O nmoliL respectively. Tacrolimus was also shown to 
inhibit IL-2 production almost completely at concentrations 
higher than 0.3 nmoliL. With an IC;o value of approximately 
().l nmoliL, tacrolimus was reported to be approximately 
1 ()O times more potent than cyclosporine, which had an 
le;o value of lOnmoliL. Tacrolimus demonstrated a similar 
inhibitory effect on interferon (IFN)-y production. 
In a separate study, tacrolimus inhibited the proliferation 
of murine spleen B lymphocytes induced by anti-mouse 
IgM by approximately 50% in vitro (40). 
In vivo animal studies have investigated the effect of 
tacrolimus on humoral and cellular immunity. In one study, 
mice were immunized with sheep erythrocytes and received 
tacrolimus and cyclosporine orally for 4 days from the 
day of immunization (1). After 4 days, tacrolimus almost 
completely suppressed splenic antibody-forming cell (AFC) 
response at doses of lOmg/kg or more, whereas cyclo-
sporine almost completely suppressed AFC response at 
100 mg/kg. Tacrolimus also suppressed delayed-type hyper-
sensitivity (DTH) responses dose-dependently in mice 
immunized with methylated bovine serum albumin 
(MBSA). 
The effect of tacrolimus on transplantation of the liver, 
kidney, heart, islet cells, and abdominal visceral organs has 
been widely studied in different animal models (41-46). In 
a liver transplantation study using beagle dogs, 8 of 10 dogs 
(80%) receiving tacrolimus survived longer than 30 days, 
providing an early in vivo demonstration that tacrolimus, 
1.0mg/kg, was as potent as cyclosporine, 20mg/kg (42). 
Tacrolimus exhibited similar immunosuppressive effects in 
cynomolgus monkeys undergoing orthotopic liver trans-
plantation (43). 
Tacrolimus has also shown promise in animal models of 
cardiac transplantation. The hearts of F344 rats were het-
erotopically transplanted into the cervical region ofWKA 
rat recipients receiving either tacrolimus or cyclosporine 
orally (4). Both agents prolonged acceptance of the cardiac 
allografts. Tacrolimus significantly prolonged graft survival 
in rats receiving a heterotopic cardiac transplantation across 
a strong major histocompatibility complex (MHC) barrier 
at a dose of 1.28mg/kg/day (44). When a moderate his-
toincompatible combination was used, the animal recipients 
survived indefinitely. 
In renal transplantation studies using tacrolimus in unre-
lated beagle dogs, all the animals in the control group died 
of renal failure due to graft rejection within 24 days; 
whereas, animals treated with 1.0mg/kg/day oral dosage of 
tacrolimus survived over 140 days after transplantation (3). 
The effect of tacrolimus in kidney transplantation was also 
studied in baboons (46). In the tacrolimus groups, 3 of 5 
(60%) and 4 of 5 (80%) animals survived longer than 80 
Cilapter 9 Tacrolimm 129 
days, depending on the dose. All of the :mimals in the 
control group died within 14 days of renal failure due to 
graft rejection. This preclinical trial in subhuman primates 
suggested that tacrolimus was a promising drug for LISe in 
humans. 
Preclinical studies of tacrolimus in intestinal transplan-
tation also have been promising (47,48). The efficacy of 
tacrolimus in several experimental animal models of allo-
transplantation is summarized in Table 9.2 (49). 
EARLY CLINICAL EXPERIENCE 
IN TRANSPLANTATION 
Most early clinical experience with tacrolimus was gained 
from the pioneering work at the University of Pittsburgh 
in liver, renal, heart, and small bowel transplantation. Initially, 
tacrolimus was used as rescue therapy in patients experi-
encing rejection or toxicity while being treated with 
cyclosporine. Subsequent trials were expanded to the use of 
tacrolimus as primary immunosuppression (52-54). This 
early experience helped to identifY the safety and tolerabil-
ity of tacrolimus as well as its role as primary and rescue 
therapy following transplantation (Table 9.3). 
CLINICAL EXPERIENCE WITH TACROLIMUS 
FOR SOLID ORGAN TRANSPLANTATION 
Liver 
Until recently, most clinical experience with tacrolimus had 
come from its use in liver transplantation as either primary or 
rescue therapy. Two prospective randomized trials conducted 
in the United States and Europe found that patient and graft 
survival were comparable with tacrolimus and cyclosporine 
but that the incidence of rejection, both acute and steroid 
refractory, was significantly lower with tacrolimus (55,56). 
The US open-label, randomized, multicenter trial com-
pared the efficacy and safety of tacrolimus to a cyclospor-
ine (Sandimmune)-based immunosuppressant regimen in 
patients undergoing primary liver transplantation (55). Adult 
and pediatric patients were randomized at the time of trans-
plant to tacrolimus (n = 263) or cyclosporine (n = 266) and 
followed for 12 months. Study end points were patient and 
graft survival and the incidence of acute, steroid-resistant, 
and refractory rejection. Patient and graft survival at 1 year 
were comparable for the tacrolimus and the cyclosporine 
groups (Fig. 9.1). Acute and steroid-resistant rejection and 
treatment failure due to refractory rejection were signifi-
cantly lower with tacrolimus. Longer-term follow-up of 
these recipients now suggests a survival benefit for the 
tacrolimus-treated patients, compared to the Sandimmune-
treated group (57). There also appears to be a significant 
benefit for the tacrolimus-treated liver allograft recipients 
with hepatitis C. Their 5-year survival rate was 78%, 
versus only 60% for the Sandimmune-treated HCV-positive 
patients. 
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Table 9.2- Tacrolimus in Experimental Allotransplantation 
Strain 
Animal Organ (ReterelKe) Donor Recipient Dose (mglkg/day) 
Rat Heart (50) ACI LEW 0.0 6.0 
0.6 1M 0-13 39.0 
1.3 1M 0-13 87.0 
1.3 1M 4,5,6 91.0 
liver (41) ACI LEW 0.0 10.0 
1.3 1M 4,5,6 >100.0 
Intestine (47) BN LEW 0.0 11.7 
0.6 1M 0-13 >100.0 
1.3 1M 0-13 >100.0 
LEW BN 0.0 12.0 
0.6 1M 0-13 27.3 
Multivisceral (51) BN LEW 0.0 10.6 
1.3 1M 0-13 >100.0 
Dog Kidney (5) Mongrel Beagle 0.0 13.0 
0.5 PO 1-90 33.7 
1.0 PO 1-90 31.0 
1.5 PO 1-90 61.0 
2.0 PO 1-90 32.1 
1.0 1M 4,5,6 58.0 
liver (5) Beagle Beagle 0.0 12.4 
1.0 PO 1-90 66.5 
1.0 1M 4,5,6 96.6 
Intestine (42) Mongrel Mongrel 0.0 7.8 
0.1 IV 1-90 57.5 
0.2 IV 1-90 23.3 
1.0 1M 3,4,5 17.7 
Baboon Kidney (46) Papio abunus Papio abunus 0.0 9.2 
6.0 PO 1-90 29.5 
12.0 PO 1-90 70.8 
18.0 PO 1-90 74.6 
2.0 1M 4,5,6 53.3 
LEW = Lewis; BN = Brown-Norway. 
Adapted from Todo 5 and Murase N. Tacrolimus for experimental organ transplantation. In: Lieberman R. Mukherjee A, eds. Principles of drug development in trans· 
plantation and autoimmunity. New York: RG Landes, 1996. 
Table 9.3. 
Transplantation 
liver 
Kidney 
Heart 
Intestine 
Bone marrow 
Lung 
Potential Uses for Tacrolimus 
Autoimmune Diseases 
Psoriasis 
Uveitis 
Chronic inflammatory diseases of the liver 
Nephrotic syndrome 
Among pediatric patients, there was a trend toward 
less rejection and a reduced requirement for steroids with 
tacrolimus, although patient and grait survival were compa-
rable (58). Major neurologic events and diarrhea were more 
common with tacrolimus, while hirsutism and higher serum 
cholesterol levels were reported with cyclosporine. 
In a parallel study conducted at eight European 
transplant centers, 545 patients were randomized to tacro-
limus or a conventional cyclosporine (Sandimmune)-based 
regimen (56). The primary end points were acute, refractory 
acute, and chronic rejection at 12 months. The rates of 
rejection were significantly lower with tacrolimus. Patient 
and grait survival rates were not different between tacro-
limus and cyclosporine. The mean corticosteroid dosage 
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FIG U R E 9. 1 • Patient survival (A) and graft survival (B) in patients treated with FK506 or cyclosporine-based «(sA) immunosuppression 
(55). Kaplan-Meier estimates of I-year patient and graft survival after liver transplantation were not significantly different between treatment 
groups. 
was significantly lower and almost no azathioprine or anti-
lymphocyte globulin was required in the tacrolimus group 
compared with the cyclosporine group. 
In the European experience, patients transplanted for 
fulminant hepatic failure had a particularly impressive 
response to tacrolimus (59). At 1 week, patient survival was 
95.5% with tacrolimus and 82.1 % with cyclosporine; by 6 
months, survival was 72.7% with tacrolimus and 60.7% with 
cyclosporine (Fig. 9.2). Similar results were observed for graft 
survival. Also, the incidence of treated rejection episodes was 
significantly reduced with tacrolimus. This resulted in a lower 
mean daily corticosteroid requirement for tacrolimus- versus 
cyclosporine-treated patients (69mg/day versus 150mg/day) 
and was reflected in a lower incidence of infectious compli-
cations with tacrolimus. 
A limitation of these studies was the comparison of 
tacrolimus to Sandimmune, rather than to N eoral therapy 
(see also Chapter 6). More recent trials suggest a lower inci-
dence of rejection in tacrolimus-treated liver allograft recip-
ients in comparison to those treated with Neora!, but these 
studies have not yet been completed. 
Rescue Therapy Following Liver Transplantation 
Tacrolimus in combination with corticosteroids proved to 
be an effective immunosuppressant regimen for rescue 
therapy in patients with rejection on a cyclosporine-based 
regimen after liver transplantation (53). Included were 72 
patients with acute rejection, 131 with chronic rejection, 
and 43 patients with either co-morbid disease or severe 
cyclosporine-related side effects. At a median follow-up of 
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240 days, 87% of patients were alive and 79% had func-
tioning grafts, Graft loss was greatest among patients with 
chronic rejection and a serum bilirubin >2.5 mg/ dL (28%) 
at the start of tacrolimus therapy and among those with viral 
hepatitis (19%). 
An open-label, multicenter study evaluated the safety 
and efficacy of tacrolimus plus corticosteroids for rescue 
therapy in 300 adult and 86 pediatric liver transplant recip-
ients experiencing refractory rejection despite conventional 
immunosuppression (60). All patients were followed for 1 
year after conversion to tacrolimus. Of these patients, 260 
completed a I-year follow-up on tacrolimus. Patient survival 
at 1 year was 74.5% for adults and 79.8% for children, and 
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graft survival at 1 year was 64.7% for adults and 67.9% for 
children. When outcomes were stratified by baseline total 
bilirubin levels >6 or <6 mg/ dL and by acute versus chronic 
rejection, patient and graft survival were consistently lower 
in patients with bilirubin levels >6 mg/ dL. 
Kidney 
An early multicenter, open-label trial compared varIOUS 
tacrolimus dosages with cydosporine in 120 patients 
undergoing primary cadaveric kidney transplant (19). 
Patients were randomized to a cydosporine-based regimen 
or to one of three tacrolimus-based regimens designed to 
achieve low (5 to 14ng/mL), medium (15 to 25 ng/mL) , or 
high (26 to 40 ng/ mL) trough whole blood levels. This trial 
revealed that the incidence of neurotoxic and gastrointesti-
nal events was higher among tacrolimus-treated patients 
during the first month after transplant and correlated with 
increasing maximum trough tacrolimus concentrations 
(P = 0.01). Also noted was a decreasing rate of rejection 
with increasing minimum trough tacrolimus concentrations 
at 1 month (P = O.l)21) (Fig. 9.3). The range of tacrolimus 
whole blood levels that optimized efficacy and minimized 
toxicity was found to be 5 to 15 ng/ mL corresponding to 
an initial oral dose of 0.2 mg/kg/ day. At 1 year, patient sur-
vival was 98% for all tacrolimus-treated patients and 92% for 
the cydosporine group. Graft survival was 93% and 89% in 
the tacrolimus and cyclosporine groups, respectively (61). 
The incidence of rejection episodes requiring treatment 
during the first year was 33% for tacrolimus and 32% for 
cyclosporine. Until day 42, the incidence of acute rejection 
was significantly lower (14% tacrolimus, 32% cyclosporine; 
P = 0.048) for the aggregate of all tacrolimus patients versus 
cyclosporine. In the tacrolimus group, 13 rejection episodes 
occurred within the first 6 weeks and 17 more were 
reported at 1 year. In the cyclosporine group, no new rejec-
FIG U R E 9. 3 • Incidence of toxicity and rejection by 
whole blood FK506 levels (19). A logistic regression analysis 
was performed to determine the relationship between 
the occurrence of rejection and toxicity, and the whole 
blood concentrations of FK506. The occurrence of toxicity 
requiring a dosage reduction increased significantly with 
increasing levels of whole blood FK506. Conversely, the 
likelihood of the occurrence of rejection decreased signifi-
cantly with increasing whole blood levels of FK506. These 
data support a recommended target whole blood FK506 
level of 5 to 15 ng/mL during the first 42 days of treatment. 
1 
.. ---_ .. _----------------, 
tion episodes were reported beyond 42 davs after transplan-
tation. Nephrotoxicity occurred with a similar frequency 
with tacrolimus and cyclosporine. but the incidence of neu-
rotoxic events and the incidence of new insulin use were 
higher among tacrolimus-treated patients. 
A subsequent randomized, open-label US study 
compared the efficacy and safety of optimal dosage 
tacrolimus to cyclosporine (Sandiml11une) immunosuppres-
sion in patients receiving cadaveric kidney transplants 
(62,63). A total of 412 renal transplant patients were ran-
domized to tacrolimus (n = 205) or cvclosporine (n = 207). 
One-year patient survival rates were 95.6'YcI for tacrolimus 
and 96.6% for cyclosporine (P = 0.576) and 1-year graft 
survival rates were 91.2% and 87.9%, respectively (P = 
0.289). Of note, biopsy-confirmed acute rejection was sig-
nificantly reduced for tacrolimus patients (30.7%) compared 
with cyclosporine (46.4%, P = 0.001), and the requirement 
for antilymphocyte therapy for rejection was also signifi-
cantly less for tacrolimus (10.7% and 25.1%, respectively; 
P < 0.001). Impaired renal function, gastrointestinal disor-
ders, and neurologic complications, which were rarely treat-
ment limiting, were common in both treatment regimens. 
Tremor and paresthesia were more frequent for tacrolimus, 
and the incidence of post-transplant diabetes mellitus was 
19.9% for tacrolimus patients versus 4.0% for cyclosporine 
(P < 0.001), but it was reversible in some patients. Hyper-
lipidemia and hypercholesterolemia were decreased in the 
tacrolimus group, and hirsutism and gum hypertrophy were 
rarely seen, resulting in a greater improvement in health-
related quality of life for these patients (64). 
The results of this study were very similar to those 
observed in the European multicenter, randomized trial that 
compared the 12-month efficacy and safety of tacrolimus 
and cyclosporine (65). In that trial, a total of 448 renal trans-
plant recipients from 15 centers received triple-drug therapy 
consisting of tacrolimus (n = 303) or cyclosporine (n = 145) 
in conjunction with azathioprine and low-dose cortico-
steroids. Twelve months after transplantation, tacrolimus 
therapy exhibited a significant reduction in the frequency of 
both acute rejection (tacrolimus 25.9% versus cyclosporine 
45.7%; P < 0.001) and corticosteroid-resistant rejection 
(11.3% versus 21.6%, respectively; P = 0.001). Actuarial 1-
year patient (tacrolimus 93.0% versus cyclosporine 96.5%; 
P = 0.140) and graft survival rates (82.5% versus 86.2%, 
respectively; P = 0.380) did not differ significantly between 
the two treatment groups. The safety profiles of the 
tacrolimus- and cyclosporine-based regimens were found to 
be comparable. No cost comparison results of either of these 
randomized studies have been reported. 
In another randomized, prospective, single center trial of 
395 adult patients undergoing renal transplantation, the 
effect of adding azathioprine to tacrolimus and steroids was 
evaluated (66).The 2-year actuarial patient and graft survival 
rates were 95% and 83%, respectively, with tacrolimus-based 
immunosuppression. There was no significant advantage in 
either patient or graft survival for patients given azathio-
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prine, but the incidence of acute rejection was slgnitlcantlv 
higher with double than with triple therapy (54'/'() versus 
44%; P < (l05). 
Tacrolimus was also evaluated as rescue therapy in 73 
patients with biopsy-confirmed renal allograft rejection 
(67.68). The median time to tacrolil11us rescue therapy was 
2.5 months (range 18 days to 48 months). At least one 
course of antilymphocyte therapy had been used III 5<) 
(81 %) patients prior to rescue. Responses to tacrolimus 
therapy included improvement in 78% of patients. stabiliza-
tion in 11 %, and progressive deterioration in 11 '%. Actuar-
ial patient and graft survival rates were 93% and 75%., 
respectively, 12 months after initiation of tacrolimus therapy. 
In a more recent report, the results of tacrolimus rescue 
therapy in 169 patients experiencing biopsy-confirmed 
rejection were summarized (69). The median time to rescue 
therapy was 2 months (range 2 days to 55 1110nths). and 
antilymphocyte preparations had been used in 144 (85%) 
patients prior to rescue. Of the 144 patients unsuccessfully 
treated with antilymphocyte drugs, 117 (81 %) were suc-
cessfully rescued with tacrolimus. Twenty-eight patients were 
on dialysis at the time of conversion, and of these 13 (46%) 
were successfully rescued. In total, 125 (74%) patients were 
successfully rescued with tacrolimus and had functioning 
grafts at a mean follow-up of 30 months. Mean prednisone 
doses decreased from 28.0 ± 9.0mg/day pre-tacrolimus to 
8.5 ± 4.1 mg/day post-tacrolimus. 
Of note, successful renal allograft function has been 
achieved with the addition of tacrolimus therapy even after 
the patient had been returned to dialysis, sometimes for pro-
longed periods (70). A review of these and other trials eval-
uating tacrolimus in renal allograft recipients has been 
recently published (71). 
Kidney-Pancreas 
Twenty-three recipients of kidney-pancreas transplants were 
studied to determine the value of tacrolimus primary 
immunosuppression in these patients (72). Of the evaluable 
patients, 10 received cyclosporine and 10 received tacrolimus 
therapy. The patient survival rate at 1 year was 100% for 
both the cyclosporine and the tacrolimus group, and the 
kidney graft survival rate was 90% for both groups. The pan-
creas graft survival rate was 80% for the tacrolimus group 
and 100% for the cyclosporine group (not significant). The 
time to the first rejection episode was significantly longer 
for tacrolimus compared to cyclosporine (23 versus 12 days, 
respectively; P = 0.026). There were no significant differ-
ences in the incidences of infectious complications or drug-
induced nephrotoxicity. 
Several other studies, with limited patient populations, 
have addressed the use of tacrolimus induction and rescue 
therapy after kidney-pancreas transplantation. In one study, 
the therapeutic effects of tacrolimus were documented in 61 
kidney-pancreas or pancreas-only transplant patients with 
relapsing and resistant cellular rejection as well as chronic 
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vascular rejection after they had been switched from 
cyclosporine-based immunosuppression (73). A subsequent 
follow-up analysis of 166 patients receiving primary 
tacrolimus therapy revealed a one-year graft survival rate of 
88% (74). Similarly, 10 kidney-pancreas transplant patients 
and 1 pancreas-after-kidney patient were converted to 
tacrolimus following acute severe cyclosporine nephrotox-
icity (75). All 11 patients were alive and 10 combined grafts 
were still functional 7.7 months after tacrolimus rescue 
therapy. All of the patients maintained stable renal func-
tion and blood glucose levels after the conversion from 
cyclosporine to tacrolimus. These observations have now 
encouraged many transplant centers to adopt tacrolimus-
based primary immunosuppressive regimens for pancreas-
kidney transplant recipients (76) (see also Chapter 21). 
Intestinal 
Because of the relatively small number of procedures per-
formed, data are more limited on the use of tacrolimus 
as immunosuppression following intestinal transplantation. 
Nevertheless, a few reports are available summarizing the 
results in both adults and children. In an initial report, 
tacrolimus was used as primary immunosuppression in 12 
adults and 11 children who underwent small bowel, small 
bowel and liver, or multivisceral transplants (77). At a 
minimum follow-up of 2 months, 19 of 23 patients were 
alive. In a follow-up that included 15 small bowel recipients 
from the earlier report, patient and graft survival were 70% 
and 66%, respectively, at 18 months after transplant (78). This 
experience, now expanded to 98 consecutive recipients of 
intestine, liver and intestine, or multivisceral allografts, was 
recently updated to reveal actuarial 1- and 5-year survival 
rates of 72% and 48%, respectively (79). As discussed in 
Chapter 22, these and other reports have concluded that 
tacrolimus-based immunosuppression provides a higher sur-
vival rate following intestinal transplantation than any other 
currently available regimen. 
Heart-Lung 
In an open-label study, tacrolimus was evaluated as primary 
immunosuppression in 62 adult heart transplant recipients 
and as rescue therapy in an additional 10 patients (80). At a 
mean follow-up of 1 year, patient survival was 92%. The 
mean number of rejection episodes was 0.95 per patient 
during the first 90 days, and recurrent rejection occurred 
in 28% of patients. Among the 10 patients receiving rescue 
therapy, 7 remained free trom rejection on tacrolimus. In 
another study of tacrolimus rescue therapy for 16 heart and 
15 lung recipients suffering acute or humoral rejection 
while on cyclosporine, patient survival rates of 100% in 
the heart recipients and 67% in the lung recipients were 
achieved (81). 
Tacrolimus was used as primary immunosuppression in 
26 pediatric heart transplant recipients (H2). Patient survival 
was 82% at 1 and at 3 years, and 60% of patients were 
rejection-free at 3 and 6 months after transplantation. 
Seventy-four adult patients were randomly assigned to 
tacrolimus or cyclosporine following single or bilateral 
lung transplant (83). One-year patient survival was similar 
between groups, but the number of patients free from 
acute rejection was significantly higher (P < 0.05) in the 
tacrolimus group. One patient (3%) in the cyclosporine 
group versus 5 of 38 (13%) in the tacrolimus group 
remained free from acute rejection during the first 120 days 
after transplant (P < 0.05). More patients in the cyclosporine 
group experienced bacterial infection, which was the major 
cause of late graft failure in both groups. A follow-up report 
of 133 patients reported similar 2-year survival rates for 
tacrolimus and cyclosporine but with a trend toward 
lower acute rejection rates with tacrolimus (84). Thirteen 
cyclosporine-treated patients versus 2 tacrolimus-treated 
patients required crossover to the alternative therapy (P = 
0.02). The incidence of obliterative bronchiolitis was signif-
icantly lower with tacrolimus (P = 0.025). 
Tacrolimus and cyclosporine were evaluated as primary 
immunosuppression in 20 pediatric lung transplant patients 
(85). Eight patients on each drug survived at a mean follow-
up of 2 years after transplant. No differences in the inci-
dence of rejection were reported between groups; however, 
6 of 7 cyclosporine-treated patients and no tacrolimus-
treated patients required antilymphocyte globulin for graft 
rejection. Furthermore, 4 patients on cyclosporine versus 
none on tacrolimus developed hypertension. 
NONTRANSPLANT USES OF TACROLIMUS 
Because of its potent immunosuppressive properties, 
tacrolimus may have applications in the treatment of 
autoimmune diseases (see Table 9.3). Clinical experience 
with tacrolimus has been reported in patients with nephrotic 
syndrome, psoriasis. chronic inflammatory diseases of the 
liver, and uveitis (86-90). Seven patients with refractory 
psoriasis experienced resolution confirmed with skin biopsy 
following treatment with tacrolimus (87). A marked reduc-
tion in proteinuria was observed in 6 of 7 patients with 
nephrotic syndrome, and the response was sustained for 6 
months (86). 
Ten patients with primary sclerosing cholangitis were 
treated with tacrolimus for up to 1 year (84). Serum biliru-
bin, alkaline phosphatase, and transaminase levels were 
reduced by 70% to 86%. No adverse effects on serum cre-
atinine or blood urea nitrogen were observed with 
tacrolimlls. In a second triaL 21 patients with autoimmune 
chronic active hepatitis were treated with tacrolimus tor up 
to 3 months (90). Transaminase levels were reduced by 70% 
to 80%, with minimal increases in serum creatinine and 
blood urea nitrogen levels. 
Tacrolimus was used to treat 13 patients with retractory 
uveitis and produced improvement in visual acuity during 
6 weeks of follow-up (91). 
Tacrolimus also has been investigated for prevention 
of graft-versus-host disease in patients undergoing bone 
marrow transplantation (92). In tim pilot study. 18 patients 
were randomized to tacrolimus alone or with methotrexate 
or methylprednisolone. Eight of 18 patients developed grade 
II-IV acute graft-versus-host disease. and 1-year disease-free 
,urvival was 39%. 
SAFETY ITOLERABILITY PROFILE 
OF TACROLIMUS 
Much of the early toxicity reported with tacrolimus was 
associated with the use of unnecessarily high intravenous 
doses. The most frequent adverse events with tacrolimus 
ill clinical trials have been renal impairment (highlighting 
the lack of correlation with blood levels), abnormalities in 
glucose metabolism, and neurotoxicity (Table 9.4) (55,56). 
III both of the liver transplant multicenter trials. the inci-
dence of abnormal kidney function in the early post-
transplant period was significantly increased with tacrolimus 
compared with the cyclosporine group. However. serum 
creatinine concentrations were not significantly different 
between treatment groups at the 12-month follow-up. The 
decrease in renal toxicity over time presumably reflected 
a decrease 111 the dose of tacrolimus and a more rapid 
conversion to oral therapy as experience with tacrolimus 
increased. 
A randomized, prospective study on the effects of 
tacrolimus immunosuppression on lipid profiles in stable 
cyclosporine-treated renal transplant patients with estab-
lished hyperlipidemia was undertaken by the Southeastern 
Organ Procurement Foundation (93). Patients with choles-
terol of240mg/dL or greater, who were at least 1 year post-
transplant with stable renal function, were randomly assigned 
Table 9.4. 
Gastrointestinal 
Anorexia 
Diarrhea 
Dyspepsia 
Nausea 
Metabolic 
Hyperglycemia 
Hyperkalemia 
Nephrotoxicity 
Neurologic 
Confusion 
Encephalopathy 
Headache 
Paresthesia 
Psychosis 
Seizure 
Tremor 
Common Adverse Events with Tacrolimus 
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to remain on cyclosporine (control) or be converted to 
tacrolil11l1s. Renal function. glucose control. and levels of 
total cholesteroL triglycerides. total high-dcnsity lipoprotcin 
(HDL), low-density lipoprotein (LDL), very-low-density 
lipoprotein (VLDL) , and apoproteins A and B were moni-
tored before conversion to tacrolimus. A total of 53 patients 
were analyzed (27 in the tacrolimus group and 2() con-
trols) 6 months after conversion. In patients converted to 
tacrolimus treatment, there was a significant decrease in 
cholesterol (16%; P = 0.0031), LDL cholesterol (25%); P = 
(l.O014), and apolipoprotein B (23%; P = 0.034). There was 
no change in renal function, glycemic control, or incidence 
of new onset diabetes mellitus in the tacrolimus group. 
The authors concluded that conversion to tacrolimus from 
cyclosporine should be considered in the treatment of post-
transplant hyperlipidemia. 
New onset diabetes mellitus and hyperglycemia occurred 
significantly more otten with tacrolimus in both the US and 
the European trial (55,56). Of concern is that many patients 
developed de novo insulin-dependent diabetes mellitus 
several months after transplantation, long after high-dose 
steroid therapy was given. However, later studies combining 
tacrolimus with mycophenolate mofetil (MMF) suppression 
indicate the incidence of insulin-dependent diabetes is 
reduced to 10% or less (94). The incidence of neurologic 
adverse events, including tremor and paresthesia, was 
significantly higher with tacrolimus, but the events were 
generally of mild or moderate severity. However, severe neu-
rologic adverse events-such as convulsions, confusion, psy-
chosis, encephalopathy, and even coma-were also seen, and 
they responded to a reduction in tacrolimus dosage. In the 
European trial, a decreased incidence of infection was 
reported with tacrolimus, while in the US study the inci-
dence of both malignant and nonmalignant neoplasms was 
lower with tacrolimus. In a 2-year follow-up of the US 
study, a higher incidence of post-transplant hepatitis C was 
reported in the tacrolimus group, and the incidence of rejec-
tion was higher in this subpopulation of tacrolimus-treated 
patients. Whether hepatitis C is a more serious problem in 
those receiving tacrolimus than in those receiving cyclo-
sporine is presently being debated (95,96). 
Pediatric patients receiving tacrolimus following liver 
transplantation have experienced an increased incidence of 
neurotoxicity, diarrhea, and dyspepsia; however, the inci-
dence of infectious complications was similar to that with 
cyclosporine (97). In contrast, a higher incidence of viral 
infections was reported in pediatric patients undergoing 
kidney transplantation (70). Of particular concern is the 
high incidence of lymphoproliferative disease, which may 
approach 10% in the pediatric population (98,99), and 
the occasional development of red cell aplasia (100) or 
hemolytic uremia (101). Because a large proportion of chil-
dren are Epstein-Barr virus (EBV) seronegative and, thus. at 
risk for primary infection leading to an increased risk of 
post-transplant lymphoproliferative disease, a role for EBV 
prophylaxis needs to be clarified (see also Chapter 20). 
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DOSING AND ADMINISTRATION 
Because of good intestinal absorption, intravenous adminis-
tration of tacrolimus is generally not required in the 
immediate postoperative period, when tacrolimus can be 
administered through the nasogastric tube, The initial dose 
of tacrolimus is 0.05 mg/kg every 12 hours, with subsequent 
dosage adjustment depending on the measured blood levels. 
The targeted tacrolimus whole blood level is initially 10 to 
20 ng/mL. After 4 weeks the recommended trough level is 
5 to 15 ng/ mL. The optimal long-term trough level has not 
yet been well defined. However, in many patients with stable 
allograft function we see tacrolimus trough levels measuring 
less that 5 ng/mL, which is below the reliable threshold of 
the current assay. With improved monitoring techniques, 
the therapeutic requirements should be better defined in the 
future. 
Pediatric patients have higher clearance and larger 
volumes of distribution than adult patients and thus require 
at least two and sometimes three daily full oral doses of 
tacrolimus to maintain adequate whole blood concentrations 
(58). Also, pediatric patients are immunologically more 
active and often require higher drug levels to prevent rejec-
tion. Generally, intravenous administration is only required 
in patients who experience gut complications after trans-
plantation. In those circumstances. the tacrolimus dose is 
0.01-0.05 mg/kg per day by continuous infusion. In patients 
with impaired hepatic function or in patients with stage 
III-IV encephalopathy. tacrolimus should be initially with-
held and an induction protocol using antilymphocyte 
antibodies considered (see Chapter 13). Also, in patients 
receiving suboptimal donor organs the tacrolimus starting 
dose should be reduced. 
It should be recognized th:lt the bioavailability of 
tacrolimus is highly variable. and ordinary doses can quickly 
make a patient profoundlv toxic. Thus. caretul monitoring is 
mandatory in all cases tollowing initiation of therapy. Some 
patients require an inordinate amount of tacrolimus to 
produce therapeutic levels (e.g., U.2-0.3 mg/kg twice daily). 
In such patients. ketoconazole. itraconazole. or diltiazem 
have been used dfectively to inhibit the metabolism of 
tacrolimus and allow normalization of the dose require-
ments. This can be lccomplished without any side effects 
from the antltungll medication. 
During ll1itiation of tacrolimus therapy lnd belore stable 
tissue levels have been achieved. large dosage changes otten 
;tre neCessarv. Generlllv. a 3()% to 4()'){, change in dosage 
.lChieves the desired results. With mble. well-maintained 
pltiems. when tille tun1l1g IS desired. sl1ull dosage adjust-
ments of 1 mg at a time an.: appropriate. In patients whose 
tJcrolimus levels are quickly escalating-tor eXlmple. during 
perIods ot' sudden detenOrltlOn of liwr ttmction-the 
t3crolimus dose should be entirely withheld umil nontoxic 
levels have been restored. This can sometimes tJke several 
,i.lVS. depelldll1~ 011 the extent Jnd dCf!ree of livcr t:lilure. It 
ukcs S h.!lf·lives ot' allv druf! betore :l new stead\' sute has 
been achieved. and in patients with advanced liver failure, 
the half-life of tacrolimus could easily reach 60 hours. 
The most difficult side etfect to manage with tacrolimus 
is minor neurotoxicity, especially in elderly patients. Minor 
neurotoxicity can be subtle. and the physician may not 
notice any abnormal behavior on casual examination. At 
times, a detailed interview of family and friends may be nec-
essary to identify the cause. This toxicity can occur even 
with low therapeutic levels of tacrolimus, and its existence 
may warrant a further dosage decrease, even with blood 
tacrolimus levels of 5 ng/ mL or less. If tacrolimus is not tol-
erated, one can always switch to cyclosporine. Although 
cyclosporine also causes neurotoxicity, the signs and symp-
toms are often different and thus may be relieved by using 
the alternate drug. 
The role of triple therapy in tacrolimus protocols has not 
been extensively investigated. However, it is clear that the 
addition of azathioprine and MMF to the immunosuppres-
sive regimen can be beneficial in tacrolimus-treated patients 
and may limit troublesome toxicity (94). However, with 
potent drugs such as tacrolimus and mycophenolate mofetil. 
one of the most common side effects in immunosuppressed 
patients is overimmunosuppression, which leads to infections 
and malignancies. Thus, initiation of a triple drug regimen 
must be done with utmost care. 
COMMENTARY 
T7lomas E. StaTzl alld joh" J. Fung 
Klintmalm's chapter contains useful information, the 
exploitation of which requires an understanding of the 
management principles that have guided organ trans-
plantation since its inception. Only four drugs have been 
widely used as baseline immunosuppressants: azathio-
prine. cyclophosphamide. cyclosporine, and tacrolimus. 
With each agent. the dosage must be determined indi-
vidually for every patient. The ceilings are imposed by 
toxicity. and the dose floors are revealed by breakthrough 
rejection. The amount of azathioprine and cyclophos-
phamide that can be given is limited by myelotoxicity, 
which call be monitored conveniently with serial 
white blood counts. The more complex side effects of 
cyclosporine and tacrolimus are shown in Table 9C.1. 
HISTORICAL PERSPECTIVE 
None ot' the tour baseline drugs c:m reliably prevent 
post-transplant rejection when used alone. However, it 
was h:arned in 1962 to 1963 that organ rejection, which 
previouslv hld been considered inexorable. could be 
reversed and that subsequent dose requirements of 
immunosuppressIve agents trcqucntly declined. The same 
events luve bet:ll observed with all treatment regimens 
.llld \\'ith :Ill or~gllsK Delineation of this pattern of con-
valescence. which was first observed \vith the combina-
tion of azathioprine and prednisone (1), provided the 
empirical launching pad for the clinical field of organ 
transplantation. in which dose-maneuverable prednisone 
has proved to be the indispensable ingredient. 
The introduction of each new drug was accompanied 
by an easily learned trial and potential error determina-
Table 9(.1. 
All Dose-Related 
Nonimmunologic Profile (4+ = Worst), 
Tacrollmus Cydosporine 
Nephrotoxicity ++* ++ 
Neurotoxicity + + 
Diabetogenicity + + 
Growth effects 
Hirsutism 0 +++ 
Gingival hyperplasia 0 ++ 
Facial brutalization 0 + 
Hepatotrophic effects ++++ +++ 
Gynecomastia 0 + 
Other metabolic effects 
Cholesterol increase 0 ++ 
Uric acid increase +? ++ 
• Less hypertension. 
Sources: From Starzl TE. Abu-Elmagd K. Tzakis A. et al. Selected topics 
on FK 506: with special references to rescue of extrahepatic whole 
organ grafts. transplantation of "forbidden organs." side effects. 
mechanisms, and practical pharmacokinetics. Transplant Proc 
1991 ;23:914-919. (Slide presented at the Transplantation Society 
Congress, San Francisco. in August, 1990.) 
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non of the requisite doses of the individual constituents 
of the cocktail. With increasingly potent baseline agents. 
survival of all organ grafts rose in three distinct leaps over 
a 33-year period. The characteristic immunologic COI1-
frontation and resolution process did not change----it 
merely became easier to manage. 
What was being accomplished through this process 
remained enigmatic until it was discovered ill 199::! that 
long-surviving organ recipients had donor leukocvte 
chimerism in their blood. skin, lymph nodes, and other 
sites as late as three decades after transplantation. It was 
then obvious that the prototypic post-transplant phe-
nomena were the product of a double immune reaction: 
host-versus-graft (rejection) and graft-versus-host (Fig. 
9C.l). Potentially tolerogenic "passenger leukocytes" of 
bone marrow origin, including pluripotent stem cells, 
had migrated from organs and engrafted peripherally. This 
was the seminal mechanism of organ allograft acceptance 
(2). 
The Tacrolimus Pilot Trials 
The clinical development of tacroJimus bracketed the 
chimerism discoveries, beginning 3 years before and con-
tinuing for 5 years after. In 1989, we first showed that 
tacrolimus (FK506) could systematically reverse liver allo-
graft rejection that had been intractable in the face of 
maximal cyclosporine-based conventional immunosup-
pression (3,4). The "rescued" patients were maintained 
thereafter on tacrolimus, and manifested no unique or 
unexpected toxicity (5). Consequently, a nonrandomized 
trial was begun in which tacrolimus was substituted for 
cyclosporine from the time of operation. 
.-,_ .•. _.-.-._. 
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FIG U R E 9 ( • 1 • Contemporaneous host-versus-graft (HVG) and graft-versus-host (GVH) reactions in the two-way paradigm of trans-
plantation immunology (2). Following the initial interaction, the evolution of nanreactivity of each leukocyte population to the other is seen 
as a predominantly low-grade stimulatory state that may wax and wane, rather than as a deletional one. 
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By early 1990, nearly 200 liver, kidney, and other-
organ recipients who had been entered in the program 
had superior actuarial survival, lower requirement for 
prednisone, and better quality of life than we had 
observed in the past (6-8). Already the upgrading of 
outlook after liver transplantation was as obvious as it had 
been a decade before when cyclosporine succeeded aza-
thioprine as the baseline immunosuppressant (Fig. 9C.2). 
Thus, even as the advent of cyclosporine had elevated 
transplantation of cadaver kidneys from a previously unac-
ceptable level (9,10), the bar rose for liver and for kidney 
transplantation with the introduction of tacrolimus (Fig. 
9C.3). The same was true for thoracic organs (8). 
It was clear by early 1990 that the dose-limiting side 
effects of cyclosporine and tacrolimus were the same: 
nephrotoxicity, neurotoxicity, and diabetogenicity (see 
Table 9C1). These manifestations could be used trom the 
first day of treatment to determine appropriate doses 
(6-8,11,12). Invidious toxicity comparisons between 
100 
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cyclosporine and tacrolimus were unwarranted because 
the scales could be tilted one way or the other by ratch-
eting the doses up or down. The only adverse effects 
observed exclusively with one drug but not the other 
were the dose-related cosmetic changes caused by 
cyclosporine (see Table gel). 
As had been found a decade earlier with cyclosporine 
(11), it was easy to relate toxic manifestations and rejec-
tion to trough plasma and blood concentrations (the 
plasma/blood ratio of tacrolimus was about 1: 10) and 
promptly endow the laboratory results with clinically rel-
evant meaning (6-8,12,13). Flexibility of dosing was 
important no matter what the transplanted organ, but 
it was especially so with the liver because the metabo-
lism of tacrolimus is more dependent than that of 
cyclosporine on good hepatic function (12,14). By the 
beginning of 1990, doses and trough levels used for liver, 
kidney, heart, and lung recipients in Pittsburgh (6,7) 
were essentially the same as those recommended in 
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FIGURE 9C.2. The three eras of ortho-
topic liver transplantation at the Universities 
of Colorado (1963-1980) and Pittsburgh 
(1981- 7 993), defined by azathioprine, cyclo-
sporine, and tacrolimus (FK 506) immuno-
suppression. A. Patient survival. B. Graft survival. 
This was about 10% lower than patient survival 
in both the cyclosporine era (1980-7989) and the 
tacroJimus era (1989-1993), whereas patient and 
graft survival were essentially identical with aza-
thioprine. The difference in later series was 
explained by effective retransplantation, an 
option that did not exist previously. AZA, azathio-
prine; CYA, cyclosporine; TAe tacrolimus. 
Klintmalm's chapter. The data shown in Figure 9C.4 were 
presented on April S. 199(). at the American Surgical 
Association. and were published 4 months later. 
The Randomized Liver Trials 
Historically, new immunosuppressive drugs were evalu-
ated in kidney recipients and then applied secondarily to 
transplantation of unpaired vital organs. This precedent 
was broken with the development of tacrolimus, largely 
because liver trallSplant surgeons demanded that the drug 
be released for rescue therapy of their patients. Rather 
than pursuing the question of rescue efficacy, it was 
decided at meetings with the United States Food and 
100 
80 
Drug Administration 
November of lSlHSl 
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(FDA) during October and 
to proceed with randomized 
European and American multicenter trials comparing 
tacrolimus with cvdosporine as the primarv immuno-
suppressant from the time of liver replacement. By the 
time these trials started the following autUJ11n. however. 
a decisive trial that had started in February 1 <J9() in Pitts-
burgh using the tacrolimus doses shown in Flgure 9C.4 
was more than half completed. 
The Pittsburgh Liver Trial 
The Pittsburgh Liver Trial was a single-center, Insti-
tutional Review Board (IRB)-mandated trial. Safety and 
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F I Ci U R E 9 C • 3 • (A) Patient sur-
vival and (B) graft survival after pri-
mary cadaveric kidney transplantation 
at the University of Pittsburgh under 
cyclosporine (1981-1989) versus 
tacrolimus-based immunosuppression. 
These observations suggest the long-
term survival of kidney allografts can 
also be improved by substitution of 
tacrolimus for cyc/osporine. Graft sur-
vival curves for azathioprine in A are 
from Terasaki's national register. Early 
patient survival data are from the 
Southeastern Organ Procurement Foun-
dation, to which Pittsburgh contributed. 
TAC, tacrolimus; CyA cyclosporine; AZQ, 
azathioprine. 
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FIG U R E 9 C. 4 • The tacrolimus 
doses used in the Pittsburgh Liver Trial and 
initially recommended far recipients of 
other organs. Because of the dependence 
on good hepatic function for tacrolimus 
metabolism, starting doses for liver recipi-
ents are slightly lower. 
FIG U R E 9 ( • 5 • The Pittsburgh Liver 
Ad hoc Dose 
Adjustments 
Ad hoc Dose 
Adjustments 
Trial protocol, tacrolimus (FK506) versus 
cycJosporine (eyA). All treatment variables 
except for the competing drugs were 
equalized. 
efficacy comparisons were ensured by equalization of all 
treatment variables except the competing drugs (15,16) 
(Fig. 9C5). Definition of end points allowed the liver 
recipients early access to whichever drug had the better 
therapeutic margin. The trial was prematurely terminated 
in 1991 by a multi-institutional oversight committee, 
which had been insisted upon by the investigators. By 
the time the trial was stopped, a massive crossover trom 
cyclosporine to tacrolimus had occurred, with only one 
crossover trom tacrolimus to cyclosporine. Throughout 
the entire 5-year period of subsequent study. tacrolimus 
enjoyed a statistically significant greater freedom from 
rejection, either alone or in combination with freedom 
trom graft loss and adverse events (16). 
The Multicenter Liver Trials 
The design of the subsequent American (17) and Euro-
pean (18) 1 iver transplant trials. which involved 20 insti-
tutions, was of some concern. In all 20 participating 
centers, the cyclosporine arm was uploaded with twice 
(or more) the induction doses of prednisone used for the 
tacrolimus patients. The cyclosporine-treated recipients 
also were given a third drug (azathioprine) in 95% of the 
centers and a fourth agent (polyc1onal ALG) in a few 
(Fig. 9C6). The tacrolimus doses were set higher than 
those concurrently used in Pittsburgh, and they remained 
so until the end of the study (Fig. 9C7). The combina-
tion of excessive dosage and the sometimes delayed 
response to toxic events on the tacrolimus arm compli-
cated the interpretation of some observations. 
The European teams had a 5% better survival of 
patients on the tacrolimus arm I 17'X) (46/270) versus 22% 
(61/275) mortality] and a 5% higher graft sllrvival (18). 
By intent-to-treat analysis. the survival advantage was not 
statistically signiticant. However. about 10% of the sur-
viving gratts credited to cyclosporine had been resclled 
trom treatment Llilure with tacrolimus. The distorting 
--------------~------- ------------_._---------------------
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FIG U R E 9 ( • 6 • US protocol in the multicenter tacrolimus (FK506) trial. The cyc/osporine (CyA) arm was uploaded with twice (or more) 
the induction doses of prednisone used for the tacrolimus patients. Cyc/osporine recipients also were given a third drug (azathioprine) in 95% 
of the centers; polyc/onal ALG was used in a few centers (n, number of centers using the regimen). 
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roles of tacrolimus overdosage and the consequent high 
rate of toxicity were clarified by separate analyses of the 
early (high dose) and later (reduced dose) phases of the 
trial. The statistical analysis, based on the intent-to-treat 
approach, showed signifIcantly greater freedom from 
acute rejection. intractable acute rejection, and chronic 
rejection. The report concluded that tacrolimus had supe-
rior therapeutic qualities (18). 
9/13/92 4/1193 
In the published American report (17), use of the 
Kaplan-Meier and intent-to-treat methods created the 
impression that the better efficacy and greater toxicity of 
tacrolimus essentially balanced each other. An alternative 
analysis suggested that freedom from rejection as a single 
end point was accomplished more frequently with 
tacrolimus (19). Moreover, the superiority of tacrolimus 
emerged at all levels, including freedom from adverse 
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events and, most significantly, freedom from refractory 
rejection. After 1 year of follow-up, 98% of the patients 
randomized to tacrolimus were not diagnosed \vith 
refractory rejection. compared with 87% in the compet-
ing arm. The composite freedom at 1 year from the 
three factors that haunt transplant recipients-refractory 
rejection. retransplantation, and death-was 80% for 
tacrolimus and 70% for cyclosporine (19). 
Randomized Trialomania 
Disquieting scientific and ethical issues were exposed by 
the events of the 6 years following the placement of 
tacrolimus on the FDA fast- track in November 1989. 
Neither the new drug's unusual rescue capability (3-5) 
nor its superiority as a baseline agent (6,7) were in doubt 
trom late 1989 onward. The evidence for this as well as 
management recommendations had been published by 
the summer of 1990 (3,6-8,12), although, as with all 
new therapies, independent confirmation was needed 
from other centers. The FDA has a range of options for 
confirmation. as shown in Table 9C.2. However, the 
agency has increasingly insisted on multicenter. con-
trolled, randomized trials as a prerequisite for marketing 
new drugs, and tacrolimus would be no different. 
The FDA feared that pilot studies might suggest supe-
riority of tacrolimus to potential multicenter participants, 
making them as reluctant as the Pittsburgh investigators 
had been to participate in a randomized triaL Therefore, 
no familiarization cases that used the drug from the time 
of transplantation were allowed. Also, by the nature of 
transpbntation biology, cocktail regimens can never be 
applil'd in exactly the same way to any two recipients. 
[n spite of this, the multicenter trial design insisted on 
rigidity of therapeutic protocols for tacrolimlls (but not 
fix thl' competing drug). 
Although the dl'sign and dosing errors of the multi-
center liver trials were ascribed to the investigators. the 
protocols and the trials themselves were efforts to comply 
with regulatory requirements. The FDA does not osten-
sibly engage in human experimentation; however, when 
Tab I e 9 ( • 2 • Spectrum of Most to Least 
"Adequate" Controls 
1. Placebo concurrent control (randomized, double-blinded). 
2. Dose-comparison concurrent control (randomized, 2 doses, often with 
placebo or active treatment arm [competing drug]). 
3. No treatment concurrent control (randomized, with no treatment arm). 
4. Active treatment concurrent control (randomized versus competing 
agent). 
5. Historical control versus concurrent treatment (special situations, when 
outcome is self-evident or in absence of equipoise). 
Code of Federal Regulations (CFR 314.126). Revised by FDA, April 1, 
1994. 
the agency imposed a learning curve for tacrolimus on 
20 different centers as a condition for the sale of a new 
drug that was urgently needed for rescue purposes, the 
agency became the de facto instigator of a human exper-
iment. It is not possible to pull this switch and disavow 
responsibility for what followed. 
Ill-advised or poorly designed randomized trials 
achieve the opposite objectives of their intent: improved 
and less expensive patient care. The lack of familiariza-
tion studies, together with the inexplicable error in 
dosing and the disadvantage of no on-site assays for drug 
monitoring, resulted in the muddled picture of the new 
drug's potential that emerged in the published literature 
between 1992 and 1995. Nevertheless, tacrolimus sur-
vived the irrational gauntlet not only because it was user 
friendly, but also because the talented group of multi-
center clinical investigators rebelled against the protocol 
and introduced treatment flexibility. This confirmed our 
earlier experience, that throughout the entire history of 
liver transplantation only two key developments have 
upgraded graft and patient survival: CaIne's introduction 
of cyclosporine in 1979 (21) and its use in combination 
with prednisone (22), and the arrival of tacrolimus (see 
Fig. 9C.2). 
Other-Organ Uses 
Following the uneven literature that came out of the 
American multicenter liver trials, an avalanche of articles 
involving organ after organ, and eventually bone marrow 
transplantation, would confirm essentially every detail of 
the original Pittsburgh experience (20). 
The same developmental leaps were seen in renal 
transplantation, for example. The 1-year cadaver kidney 
survival rate in the United States had remained fixed at 
less than 50% until the advent of cyclosporine, after 
which it rose to 77% at the University of Pittsburgh. A 
second abrupt increase to nearly 90% followed the 
routine use of tacrolimus (see Fig. 9C.3). The mainte-
nance of the gap between cyclosporine and tacrolimus 
after 1 year was congruent with the report of Gjertson, 
Cecka, and Terasaki, based on the cadaver kidney half-life 
projections trom 24 American kidney transplant centers 
with access to tacrolimus. Their suggestion was: "FK 506 
(tacrolimus) appears to be the first therapeutic agent to 
significantly improve long-term kidney graft survival 
rates" (23). A thorough review of the use of tacrolimus 
following kidney transplantJtion has been provided by 
Laskow et al (24). 
POST-TRANSPLANT 
LYMPHOPROLIFERATIVE DISORDERS 
It has not been surprising to observe an incrementJl 
increase in post-transplant lymphoproliferative disorders 
(PTLDs) with the successively more potent baseline 
immunosuppressants (21.25-27). This risk can be reduced 
at the outset by avoiding the joint use of the biologic 
antilymphoid agents (e.g .. ALG and OKT-3) in conjunc-
tlOll with cyclosponne and tacrolimus except as a last 
resort, and then only \vith extreme caution. 
When PTLD is diagnosed early in development, 
lt usually is a trivial problem requiring only drug dose 
reduction. At the Children's Hospital of Pittsburgh, 
') (13.2%) of 68 recipients (of 69 kidney allografts) 
treated with tacrolimus-based immunosuppression be-
tween 1989 and 1995 developed histopathologically ver-
ified PTLD (28). No deaths resulted, nor did any graft 
losses. All kidneys are still functioning (at the time of this 
writing) except one that was chronically rejected 3 years 
later. 
At the same institution, histopathologically verified 
PTLD was diagnosed in 28 (12. t %) of the 232 consec-
utive primary pediatric liver recipients treated with 
tacrolimus between 1989 and 1995. Although 5 of the 
28 died of potentially PTLD-related complications, the 
4-year patient and graft survival rate (82.2%) was essen-
tially the same as in the 204 non-PTLD patients (Table 
9C.3) (27). Management was facilitated by the policies of 
gradual tacrolimus dose reduction with acceptance of 
lower blood levels as time passes (see Table 9C.3), early 
discontinuance of prednisone, avoidance of adjunct agents 
including OKT-3 and azathioprine, and surveillance for 
Epstein-Barr virus (EBV) infection. 
Table 9(.3. Primary Liver Transplantation in Children 
Under Tacrolimus (n = 232)"b 
" E~~~DrID:-IMDD}~~ 
Months' Follow-Up' 
-,.Y 
3 12 24 36 48 
Survival (%) 
Patient 90.2 86 85 84 84 
Graft 83 79.2 78.2 77.3 77.3 
Taaolimus (mean) 
Dose (mg/day) 5.6 3.3 2.9 2.9 2.4 
Plasma concentration 0.84 0.56 0.43 0.4 0.24 
(trough ng/ml)' 
Prednisone (%) 
None 79 82 88 93 91 
:::;5mg/day 9 13 5 7 
>S mg/day 12 2 2 
• September 1989-January 1995, Age 5,0 ± 5.2 (SO) years (medium 
2.7), Mean follow-up 44 ± 14.6 months, 
b 28 patients developed PTLD. Principal sites were the gastrointesti-
nal system (n = 9), lymph nodes (n = 8), liver (n = 6), spleen (n = 2), 
and tonsils, skin, and blood (leukemia) (n = 1 each), 
, For approximate whole blood values, multiply by 10. 
Data from Dr. Jorge Reyes. Presented at the 2nd International Con-
gress on Pediatric Transplantation, Paris, France, August 23-24, 1996. 
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Except for their frequent EBV association, human B-
cell lymphomas are indistinguishable from those induced 
by Robert S. Schwartz in a mouse chimerism model 
(29) 3 years before they were reported in human kidney 
recipIents (30). Schwartz attributed the experimental 
tumors to an active lymphoproliferative response by the 
dominant immune apparatus to the persistent subclinical 
graft-versus-host counterattack of the minority donor 
leukocyte population. The relevance of his observations 
to clinical PTLD would only be appreciated 3() years 
later (27). after the discovery that similar microchimerislll 
was a characteristic feature of successful organ transplan-
tation (2). This fresh insight about PTLD has been used 
to map treatment strategies of cellular immune modula-
tion as discussed elsewhere (27). 
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